Literature DB >> 7520896

HLA-DR alpha chain residues located on the outer loops are involved in nonpolymorphic and polymorphic antibody-binding epitopes.

X T Fu1, R W Karr.   

Abstract

The structure-function relationships of the HLA-DR alpha chain have been analyzed by identifying DR alpha residues involved in several nonpolymorphic and polymorphic antibody epitopes. Antibody binding to transfectants expressing a WT or mutant DR alpha chain with the WT DR(beta 1*0701) chain was analyzed. Our results indicate that residues 18, 36, and 39 located on the outer loops of the DR alpha chain are critical for one or more of the epitopes recognized by the SG157, Q2/70, L243, LB3.1, D1-12, and CL413 mAbs. Similar results were obtained when the DR alpha position 18 and 39 mutants were expressed with other DR beta 1 alleles. Furthermore, residues 15 and 18 of the DR alpha chain were shown to be involved in the epitopes of two polymorphic mAbs, HU-26 and I-2, whose epitopes also include residue 4 of the corresponding DR beta chains. In addition to their involvement in antibody-binding epitopes, residues in this region on the outer surface of the DR alpha chain have also been shown to be involved in superantigen binding and presentation and T-cell recognition of foreign antigen, emphasizing the functional importance of DR alpha-chain residues located outside of the peptide-binding groove.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7520896     DOI: 10.1016/0198-8859(94)90268-2

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  17 in total

1.  A point mutation in the groove of HLA-DO allows egress from the endoplasmic reticulum independent of HLA-DM.

Authors:  Francis Deshaies; Alexandre Brunet; Djibril A Diallo; Lisa K Denzin; Angela Samaan; Jacques Thibodeau
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-22       Impact factor: 11.205

2.  Cepharanthine blocks TSH receptor peptide presentation by HLA-DR3: Therapeutic implications to Graves' disease.

Authors:  Cheuk Wun Li; Roman Osman; Francesca Menconi; Erlinda Concepcion; Yaron Tomer
Journal:  J Autoimmun       Date:  2020-01-21       Impact factor: 7.094

3.  Employing a recombinant HLA-DR3 expression system to dissect major histocompatibility complex II-thyroglobulin peptide dynamism: a genetic, biochemical, and reverse immunological perspective.

Authors:  Eric M Jacobson; Heyi Yang; Francesca Menconi; Rong Wang; Roman Osman; Luce Skrabanek; Cheuk Wun Li; Mohammed Fadlalla; Alisha Gandhi; Vijaya Chaturvedi; Eric P Smith; Sandy Schwemberger; Andrew Osterburg; George F Babcock; Yaron Tomer
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

4.  Susceptibility to HLA-DM protein is determined by a dynamic conformation of major histocompatibility complex class II molecule bound with peptide.

Authors:  Liusong Yin; Peter Trenh; Abigail Guce; Marek Wieczorek; Sascha Lange; Jana Sticht; Wei Jiang; Marissa Bylsma; Elizabeth D Mellins; Christian Freund; Lawrence J Stern
Journal:  J Biol Chem       Date:  2014-07-07       Impact factor: 5.157

5.  Characterization of a humanized IgG4 anti-HLA-DR monoclonal antibody that lacks effector cell functions but retains direct antilymphoma activity and increases the potency of rituximab.

Authors:  Rhona Stein; Zhengxing Qu; Susan Chen; David Solis; Hans J Hansen; David M Goldenberg
Journal:  Blood       Date:  2006-06-15       Impact factor: 22.113

6.  Anti-HIV designer T cells progressively eradicate a latently infected cell line by sequentially inducing HIV reactivation then killing the newly gp120-positive cells.

Authors:  Gautam K Sahu; Kaori Sango; Nithianandan Selliah; Qiangzhong Ma; Gail Skowron; Richard P Junghans
Journal:  Virology       Date:  2013-09-06       Impact factor: 3.616

7.  Replacement of the DR alpha chain with the E alpha chain enhances presentation of Mycoplasma arthritidis superantigen by the human class II DR molecule.

Authors:  T Sawada; R Pergolizzi; K Ito; J Silver; C Atkin; B C Cole; M D Chang
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

8.  Class II transactivator (CIITA) enhances cytoplasmic processing of HIV-1 Pr55Gag.

Authors:  Kristen A Porter; Lauren N Kelley; Annette George; Jonathan A Harton; Karen M Duus
Journal:  PLoS One       Date:  2010-06-24       Impact factor: 3.240

9.  Flexible peptide recognition by HLA-DR triggers specific autoimmune T-cell responses in autoimmune thyroiditis and diabetes.

Authors:  Cheuk Wun Li; Roman Osman; Francesca Menconi; Erlinda S Concepcion; Yaron Tomer
Journal:  J Autoimmun       Date:  2016-09-23       Impact factor: 7.094

10.  Identifying a Small Molecule Blocking Antigen Presentation in Autoimmune Thyroiditis.

Authors:  Cheuk Wun Li; Francesca Menconi; Roman Osman; Mihaly Mezei; Eric M Jacobson; Erlinda Concepcion; Chella S David; David B Kastrinsky; Michael Ohlmeyer; Yaron Tomer
Journal:  J Biol Chem       Date:  2015-12-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.